An antisense oligonucleotide-targeting PKCα called aprinocarsen (ISIS 3521/LY900003) was evaluated in several clinical trials for recurrent high-grade astrocytomas [423], NSCLC [424,425], ovarian carcinoma [426], prostate cancer [427], metastatic colorectal cancer [428], and NHL [429]. The gene discussed is PRKCA; the disease is prostate carcinoma.